Siemens Healthineers launches Innovance D-Dimer 2.0 assay
Sept. 30, 2026—Siemens Healthineers has launched its CE-marked, FDA 510(k)-cleared Innovance D-Dimer 2.0 assay.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears Cepheid Xpert Respiratory panel
Sept. 29, 2026—Cepheid has received FDA clearance for the Xpert Respiratory panel, a multiplex PCR test designed to detect 13 common viral and bacterial respiratory pathogens from a single nasopharyngeal swab sample.
FDA clears QIAstat-Dx bacteria detection panel
Sept. 28, 2026—The Food and Drug Administration has cleared Qiagen’s QIAstat-Dx BCID GN Plus AMR panel.
Project Santa Fe Foundation adds three board members
Sept. 18, 2026—Project Santa Fe Foundation and Clinical Lab 2.0 have added three new members to its board of directors: Mercè Jordà, MD, PhD, MBA, chair of pathology and laboratory medicine, University of Miami Miller School of Medicine; William G. Morice, MD, PhD, president and CEO, Mayo Collaborative Services/Mayo Clinic Laboratories; and Peter Weir, MD, MPH, chief population health officer, University of Utah Health.
BioFire respiratory panels get IVDR class D CE mark
Sept. 17, 2026—BioMérieux’s BioFire Respiratory 2.1 Plus and BioFire FilmArray Pneumonia Plus panels have received the CE mark under the IVDR as class D in vitro diagnostic devices, the highest risk classification under the regulation.
Siemens Healthineers releases CN-3000, CN-6000 hemostasis systems
Sept. 16, 2026—Siemens Healthineers has released the CN-3000 and CN-6000 automated hemostasis analyzers for mid- and high-volume laboratories in the United States.
ARUP study underscores value of atypical cfDNA results
Sept. 10, 2026—A research study by ARUP Laboratories clarifies the clinical value of atypical findings from prenatal cell-free DNA screening and their impact on pregnancy outcomes.
FDA clears NanoZoomer S20MD, S540MD slide scanner systems
Sept. 8, 2026—Hamamatsu Photonics has received FDA 510(k) clearance for the NanoZoomer S20MD and S540MD slide scanner systems.
FDA approves targeted therapy for metastatic pancreatic cancer
Aug. 26, 2026—The Food and Drug Administration today approved daraxonrasib (Rasonque, Revolution Medicines) for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
FDA clears the C2N Diagnostics PrecivityAD2 test
Aug. 25, 2026—The FDA has cleared C2N Diagnostics’ PrecivityAD2 test, indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.